^
Association details:
| Biomarker: | FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | luxeptinib (CG-806) (BTK inhibitor, FLT3 inhibitor, Myeloid kinome inhibitor, Lymphoid kinome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A PHASE 1A/B DOSE ESCALATION STUDY OF THE MUTATION AGNOSTIC FLT3/BTK INHIBITOR LUXEPTINIB (CG-806) IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Published date:
05/12/2021
Excerpt:
One heavily pre-treated patient with relapsed AML with mutated NPM1, DNMT3A, and FLT3-ITD who had previously progressed after chemotherapy, alloSCT, and two FLT3 inhibitors (gilteritinib, crenolanib) demonstrated clinical anti-leukemic activity with a decrease in peripheral blood blasts from 93% to 10% during Cycle 1....Luxeptinib has been well tolerated at the starting dose level of 450mg Q12 hours.
Trial ID:
